Lenz joined the WSGW team in 1978. He was the on-air personality for the “Four for the Morning” and “Terry and Dave in the ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

One Billings city official says plans for a new state mental hospital could be finalized by the end of this month, but state officials have not confirmed those plans.

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

Lenz Therapeutics (NASDAQ:LENZ) reported GAAP revenue of $5.0 million for Q2 2025, far surpassing the $0.71 million GAAP analyst estimate, due to licensing deals rather than product sales. Net ...

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

Lenz Therapeutics is a clinical-stage biotech aiming to reshape vision correction for presbyopia, an age-related loss of near vision affecting people over forty. Its lead product, LNZ100, is a ...

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ TM (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the ...

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...